Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Operating Expenses (2018 - 2024)

X4 Pharmaceuticals (XFOR) has disclosed Other Operating Expenses for 4 consecutive years, with $105.0 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Other Operating Expenses changed N/A year-over-year to $105.0 million, compared with a TTM value of $105.0 million through Mar 2025, up 91.87%, and an annual FY2024 reading of $105.0 million, changed N/A over the prior year.
  • Other Operating Expenses was $105.0 million for Q2 2024 at X4 Pharmaceuticals, up from $54.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $105.0 million in Q2 2024 and bottomed at -$509000.0 in Q4 2022.